5DG Stock Overview
Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ocumension Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.61 |
| 52 Week High | HK$0.86 |
| 52 Week Low | HK$0.47 |
| Beta | 0.80 |
| 11 Month Change | -7.52% |
| 3 Month Change | 5.13% |
| 1 Year Change | -25.00% |
| 33 Year Change | -68.13% |
| 5 Year Change | n/a |
| Change since IPO | -83.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5DG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.5% | -1.2% | -0.02% |
| 1Y | -25.0% | -20.1% | 8.2% |
Return vs Industry: 5DG underperformed the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 5DG underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 5DG volatility | |
|---|---|
| 5DG Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 5DG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5DG's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 477 | Victor Liu | www.ocumension.com |
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.
Ocumension Therapeutics Fundamentals Summary
| 5DG fundamental statistics | |
|---|---|
| Market cap | €523.12m |
| Earnings (TTM) | -€42.77m |
| Revenue (TTM) | €41.13m |
12.7x
P/S Ratio-12.2x
P/E RatioIs 5DG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5DG income statement (TTM) | |
|---|---|
| Revenue | CN¥310.29m |
| Cost of Revenue | CN¥129.44m |
| Gross Profit | CN¥180.86m |
| Other Expenses | CN¥503.58m |
| Earnings | -CN¥322.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 58.29% |
| Net Profit Margin | -104.01% |
| Debt/Equity Ratio | 0% |
How did 5DG perform over the long term?
See historical performance and comparison